Clinical trialNCT07226986RecruitingPhase 1/PHASE2Interventional

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

SponsorNovartis PharmaceuticalsEnrollment123PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Novartis Investigative Site
Malvern, Victoria, Australia
Recruiting
Novartis Investigative Site
Melbourne, Victoria, Australia
Recruiting
Novartis Investigative Site
Murdoch, Western Australia, Australia
Recruiting

France

Novartis Investigative Site
Bordeaux, France
Recruiting
Novartis Investigative Site
Clermont-Ferrand, France
Recruiting
Novartis Investigative Site
Nantes, France
Recruiting
Novartis Investigative Site
Villejuif, France
Recruiting

Germany

Novartis Investigative Site
Dresden, Saxony, Germany
Recruiting
Novartis Investigative Site
Essen, Germany
Recruiting
Novartis Investigative Site
München, Germany
Recruiting

Italy

Novartis Investigative Site
Cona, FE, Italy
Recruiting
Novartis Investigative Site
Milan, MI, Italy
Recruiting
Novartis Investigative Site
Naples, Italy
Recruiting

Japan

Novartis Investigative Site
Sapporo, Hokkaido, Japan
Recruiting

Spain

Novartis Investigative Site
Granada, Andalusia, Spain
Recruiting
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, Spain
Recruiting
Novartis Investigative Site
Barcelona, Spain
Recruiting
Novartis Investigative Site
Madrid, Spain
Recruiting

United States

Va Greater la Healthcare System
Los Angeles, California, United States
Matthew Rettig
Recruiting
Rio Grande Urology
El Paso, Texas, United States
Jameson T Mendel
Recruiting
Utah Intermountain Medical Center
Murray, Utah, United States
Dustin Boothe
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 Dec 2025
Primary completion: 10 Jul 2028
Completion: 13 Sept 2029
Last update posted: 2 Jul 2026
Registered enrollment: 123
Registry id: NCT07226986

Cross-registrations

EU-CTR / CTIS (EudraCT)2025-521859-23-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.